Loading stock data…
ALEC
$2.36-0.01 (-0.42%)
Market ClosedLast close May 1
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Alector, Inc. in the Healthcare sector is trading at $2.36. The stock is currently 31% below its 52-week high of $3.40, remaining 14.0% above its 200-day moving average. Technical signals show neutral RSI of 52 and bearish MACD signal, explaining why ALEC maintains its current momentum and trend strength. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 52) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$2.36
Potential Upside
5%
Whystock Fair Value$2.48
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus5 analysts
Hold
Mean target$2.88+22.0%
Range$0.90 – $6.00
Fundamentals
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treatin...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$269.28M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.58
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-376.16%
Volume
Today's trading volume
379,178
Recent News
How The Alector (ALEC) Narrative Is Shifting Toward BBB Shuttle Programs And Execution Risk
Alector’s refreshed analyst narrative comes with $6 price targets that are presented as more closely aligned with the company’s current therapeutic pipeline and BBB shuttle focus. Research notes link these $6 targets to a cleaner story after the frontotemporal dementia trial, with a stronger spotlight on neurodegeneration mechanisms and protein engineering strengths, alongside ongoing execution and clinical risks. As you read on, you will see how this evolving setup might shape your own view...
Discovering Middle East's Undiscovered Gems This April 2026
As April 2026 unfolds, the Middle East stock markets are experiencing a mixed yet cautiously optimistic phase, with most Gulf markets finishing higher despite lingering uncertainties over U.S.-Iran relations. This environment of cautious optimism provides a fertile ground for identifying undiscovered gems in the region's small-cap sector, where strong local fundamentals and strategic national initiatives could enhance growth potential.
Undiscovered Gems in the Middle East for March 2026
The Middle East stock markets have recently experienced a surge, with Gulf equities gaining momentum following reports of a potential US-Iran ceasefire proposal. This optimism has led to significant increases in key indices, such as Dubai's main share index, which saw its largest intraday gain since December 2024. In this dynamic environment, identifying promising stocks involves looking for companies that can capitalize on regional stability and leverage growth opportunities in sectors...
Why The Narrative Around Alector (ALEC) Is Shifting With Its BBB Shuttle Focus
Alector’s latest analyst update moves its modeled fair value from US$2.10 to US$2.88, a shift that sits between a bullish US$6 target and a bearish US$0.90 view. Both sides are reacting to the same pivot toward BBB shuttle therapeutics, but while optimistic analysts see a clearer, more focused story, cautious voices still emphasize execution risk and past trial setbacks. As you read on, you will see how to track this evolving narrative and what to watch as sentiment around Alector continues...
Wall Street Turns Bullish on HIMS, TDOC and ALEC as Partnerships Reshape Risk Profiles
Three health-technology names are drawing fresh analyst attention this week as strategic partnerships and business pivots reframe the risk-reward calculus for each. Hims & Hers Health (NYSE:HIMS) received two separate upgrades after resolving its legal dispute with Novo Nordisk (NYSE:NVO) through a distribution partnership. Teladoc Health (NYSE:TDOC) earned a Buy from Deutsche Bank on valuation ... Wall Street Turns Bullish on HIMS, TDOC and ALEC as Partnerships Reshape Risk Profiles